Torphasol 20ml

Description

Torphasol 10mg/ml solution for injection for horses use short term relief of pain associated with colic of gastrointestinal tract origin and for sedation in combination with certain α2-adrenoceptor agonists

 

Indications for use, specifying the target species

For short term relief of pain associated with colic of gastrointestinal tract origin.
For sedation in combination with certain a2-adrenoceptor agonists.

Contraindications

Butorphanol – as a sole agent and in any combination:

• Do not use in horses with a history of liver or kidney disease.
• Do not use in case of known hypersensitivity to the active substance or to any of the
  excipients.
• Do not use in cases of cerebral injury or organic brain lesions (e.g. lesions
  following cranial trauma) and in animals with obstructive respiratory diseases,
  heart dysfunction or spastic convulsions.

Butorphanol / detomidine hydrochloride combination:
The combination should not be used in pregnant animals.

• Do not use the combination in horses with a pre-existing cardiac dysrhythmia or
  bradycardia.
• Do not use in horses with emphysema due to a possible depressive effect in the
  respiratory system.

Butorphanol / romifidine combination:
– Do not use during the last month of pregnancy
Butorphanol / xylazine combination:
The combination should not be used in pregnant animals.
Any reduction in gastrointestinal motility caused by butorphanol (see section 4.6)
may be enhanced by the concomitant use of a2-adrenoceptor agonists.
Consequently, such combinations should not be used in cases of colic associated
with impaction.

Special Precautions For Use

• Special precautions for use in animals
• Safety and efficacy of butorphanol in foals have not been established. In foals use
  the product only according to the benefit/risk assessment by the responsible
  veterinarian.
• Due to its antitussive properties, butorphanol may lead to an accumulation of mucous
  in the respiratory tract. Therefore, in animals with respiratory diseases associated
  with increased mucous production or in animals that are being treated with
  expectorants, butorphanol should only be used on the basis of a risk-benefit analysis
  by the responsible veterinarian.
• The use of the product at the recommended dose may lead to transient ataxia and/or
  excitement. Therefore, to prevent injuries in patient and people, the location for the
  treatment should be chosen carefully.
  Butorphanol / detomidine hydrochloride combination:
• Routine cardiac auscultation should be performed prior to use in combination with
  detomidine.